[e-farmacos] WHO Pharmaceuticals Newsletter n2 2004

["Martin Canas" <macanas@netverk.com.ar>]

Estimadas y estimados,

Esta disponible en la red el WHO Pharmaceuticals Newsletter n2 del 2004
cuyo indice es:

REGULATORY MATTERS
BENZBROMARONE, BENZIODARONE --Measures following safety review
EPHEDRA PRODUCTS -- To be treated as medicinal products
NEVIRAPINE -- New hepatotoxicity information added to product
OLANZAPINE, RISPERIDONE -- New safety information regarding use in elderly 
patients with dementia
PAROXETINE -- Prescribing advice for use in adults
RITONAVIR & FLUTICASONE -- Concomitant use should be
TERBINAFINE -- Label to include possibility of hepatic disorders

SAFETY OF MEDICINES
ANALGESICS -- Campaign on safe use of over-the-counter pain relief
ANTIDEPRESSANTS -- Under-18 patients receiving SSRIs/SNRIs to consult 
physicians
ATYPICAL ANTIPSYCHOTICS -- Increased risk of obesity and type II diabetes
CILOSTAZOL -- Not recommended for treating intermittent claudication
CYPROTERONE -- Hepatotoxcity with high doses
ESTROGEN -- Estrogen-alone trial of WHI study halted
ISOTRETINOIN -- Tighter prescribing regulations to be considered
LEFLUNOMIDE -- Worsening of respiratory symptoms
SEROTONERGIC AGENTS -- Update on reports of serotonin syndrome

La direccion es:
http://www.who.int/medicines/library/pnewslet/2news2004.pdf

Saludos,
Martin

Martin Canas
La Plata 
(Argentina)
macanas@netverk.com.ar